Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

BACKGROUND: Nintedanib is effective for treating idiopathic pulmonary fibrosis (IPF), but some patients may exhibit a suboptimal response and develop on-treatment acute exacerbation (AE-IPF), hepatic injury, or mortality. It remains unclear which patients are at risk for these adverse outcomes. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Tang-Hsiu, Kuo, Chin-Wei, Chen, Chian-Wei, Tseng, Yau-Lin, Wu, Chao-Liang, Lin, Sheng-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126113/
https://www.ncbi.nlm.nih.gov/pubmed/33992083
http://dx.doi.org/10.1186/s12890-021-01530-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126113/
https://www.ncbi.nlm.nih.gov/pubmed/33992083
http://dx.doi.org/10.1186/s12890-021-01530-6

Ejemplares similares